I am an accomplished life science executive with a distinguished track record of commercializing disruptive technologies and managing industry-leading global product portfolios in excess of $250M. Businesses under my leadership have benefited from consistent revenue growth, increased profit margins, and expanded market share. My background includes working at startups, growth-stage, and Fortune 150 biotechnology companies, commercializing a diverse range of products and solutions within the biotechnology sector. I am recognized for my strategic thinking, delivering game-changing products, and leading teams to success. As the CEO of Aspiro Therapeutics, I am dedicated to pioneering the development of groundbreaking treatments for obstructive lung diseases. With over a decade of experience in biotech, my focus is on advancing our lead candidate, a CC16 peptidomimetic, through preclinical development with a clear pathway to clinical trials. I am committed to building strategic partnerships, securing funding, and driving our mission to bring life-changing therapies to patients worldwide.